The mechanistic link between increased FGF23 and bone remodelling reported in these preclinical studies led to clinical investigations into the association between FGF23 and osteoporosis in the elderly, CKD or end-stage renal disease (ESRD) patients, who commonly have elevated levels of FGF23, as discussed later. The gene discussed is FGF23; the disease is chronic kidney disease.